Atika Capital Management’s RxSight RXST Stock Holding History

Atika Capital Management’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-500	Closed	-$1.26M	–	73
2025 Q1	$1.26M	Buy	+500	New	+$14.9K	0.18%	58

Other funds holding RXST

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return

NSGL

No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Atika Capital Management's RXST Position: Q4 2025 in Review

Atika Capital Management sold out of RxSight (RXST) in Q4 2025, closing a stake of 354,907 shares — an estimated $3.19M sold.

Atika Capital Management first reported a position in RXST in Q2 2023 and held it in 10 quarters. The position peaked at $24.2M in Q2 2024. 163 funds tracked by Wall St. Rank hold RXST as of Q4 2025.

Atika Capital Management reported no remaining RxSight position as of Q4 2025 after selling out during the quarter.
Atika Capital Management sold 354,907 RxSight shares in Q4 2025, an estimated $3.19M.
Atika Capital Management first reported a position in RxSight in Q2 2023 and held it in 10 quarters.
Atika Capital Management's RxSight position peaked at $24.2M in Q2 2024.
163 funds tracked by Wall St. Rank held RxSight as of Q4 2025.

Based on Atika Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.